MedPath

Influence of Vitamin C on Post-operative Atrial Fibrillation

Not Applicable
Conditions
Atrial Fibrillation
Interventions
Dietary Supplement: Vitamin C
Other: Placebo
Registration Number
NCT03592680
Lead Sponsor
Algemeen Ziekenhuis Maria Middelares
Brief Summary

Post-operative atrial fibrillation (POAF) is the most common arrhythmia which typically develops 2-3 days after cardiac surgery. The incidence of POAF variates between 10% and 65% depending on the type of cardiac surgery and is especially high in patients which underwent Coronary Artery Bypass Grafting (CABG) and heart valve surgery. POAF is associated with increased morbidity and mortality and has a major impact on hospital resources.

The precise pathogenesis of POAF is very complex, but several studies have demonstrated an association between inflammation, oxidative stress and POAF. Since this oxidative stress may be reduced by dietary anti-oxidantia such as vitamin C, the aim of this study is to evaluate the effect of oral vitamin C administration of the incidence of POAF.

Detailed Description

After obtaining informed consent, patients which are planned for CABG or heart valve surgery are randomly assigned into the Vitamin C group or Placebo Group.

Each patient will receive 1 g Vitamin C or Placebo twice a day from 5 days before until 10 days after surgery. The medication will be given orally and both patient and surgeon are blinded for the administrated medication.

Patients receive standard of care in the post-operative period, which includes close monitoring for possible arrhythmias. If such an arrhythmia develops, this is treated according to the normal procedures. All information such as the used medication, the hospitalization / ICU length of stay and the ventilation time is automatically registered in the patient records.

From each patient, three additional blood samples (peri-operative, post-operative Day 0, post-operative Day 1) will be obtained for analysis of Neutrophil gelatinase-associated lipocalin (NGAL), a possible marker of subclinical kidney damage. These samples will be analysed in batch once all samples are collected.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
600
Inclusion Criteria
  • signed informed consent
  • eligible for elective cardiac surgery
  • preoperative sinus rhythm
Exclusion Criteria
  • patients who do not want to participate

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Vitamin CVitamin CVitamin C 1000mg PO from 5 days before surgery until 10 days after surgery
PlaceboPlaceboPlacebo as an alternative for Vitamin C tablets
Primary Outcome Measures
NameTimeMethod
ArrhythmiaFirst 5 days postoperatively

Incidence

Secondary Outcome Measures
NameTimeMethod
hours of endotracheal ventilationfrom arrival at ICU after surgery until the time of discharge from ICU. average 48 hours.

number of hours of endotracheal ventilation after surgery

Length of stay at ICUfrom time of arrival at ICU after surgery until the time of discharge from ICU. upto 14 days. average 48 hours.

number of hours in the Intensive Care Unit

Length of stay in the hospitalfrom time of arrival at ICU after surgery until the time of hospital discharge. upto 120 days.

number of hours in the hospital

Cost of postoperative medicationfrom time of arrival at ICU after surgery until the time of hospital discharge. upto 120 days

Total cost (€) of postoperative medication

subclinical kidney damageafter induction of anesthesia and two hours after CPB

change in Value of NGAL between pre-incision and post-CPB

Postoperative complicationsfrom time of arrival at ICU until the time of hospital discharge. upto 120 days

Number of unexpected complications requiring medical interventions

Trial Locations

Locations (1)

AZ Maria Middelares

🇧🇪

Gent, Oost-Vlaanderen, Belgium

© Copyright 2025. All Rights Reserved by MedPath